• SB525334: A Precision Tool for TGF-β1 Assays

  2026-08-17

  SB525334 is a selective TGF-beta1 receptor inhibitor for dissecting ALK5-dependent signaling in fibrosis, renal disease, and wound-healing models. This guide connects receptor-level pharmacology with the latest bone-transport diabetic foot ulcer findings to improve experimental design and interpretation.

• SB 431542: Reliable ALK5 Inhibition in Cell Assays

  2026-08-17

  SB 431542 (SKU A8249) offers a practical way to connect TGF-β receptor inhibition with interpretable cell proliferation, viability, and cytotoxicity data. This scenario-based guide covers mechanism, assay compatibility, dosing, data interpretation, and product-selection decisions for biomedical laboratories.

• Verteporfin (CL 318952) Assay Workflows

  2026-08-16

  Verteporfin (CL 318952) supports both light-triggered photodynamic experiments and light-independent autophagy studies. This workflow connects those use cases with cancer mechanobiology assays, helping researchers separate phototoxicity, cell-death signaling, and stiffness-dependent immune sensitivity.

• X-Gal Beyond Blue-White Screening: Assay Logic

  2026-08-15

  X-Gal is more than a blue-white colony screening reagent: it is a visual reporter whose chemistry defines what a cloning result can—and cannot—prove. This article connects β-galactosidase readouts with modern olfactory signaling research and provides a decision-focused framework for reliable assay interpretation.

• U0126 for Reliable MEK1/2 Assays

  2026-08-14

  A practical, scenario-based guide to using U0126 (SKU BA2003) in viability, proliferation, and cytotoxicity workflows. It connects MEK1/2 inhibition with assay compatibility, dosing, storage, interpretation, and vendor-selection decisions.

• Neurotensin: An Assay-First GPCR Roadmap

  2026-08-14

  Neurotensin is a precise Neurotensin receptor 1 activator for connecting acute GPCR signaling with receptor recycling and miR-133α modulation. This assay-first guide combines peptide handling, layered gastrointestinal readouts, and lessons from fluorescence-classification research to improve experimental interpretation.

• X-Gal: Mechanism and Blue-White Screening

  2026-08-13

  X-Gal, also called 5-bromo-4-chloro-indolyl-β-D-galactopyranoside, is a chromogenic β-galactosidase substrate used to distinguish recombinant clones. Its lacZ-dependent blue-white colony screening readout is visual, rapid, and best treated as a screening result that requires molecular confirmation.

• Melatonin, RIPK3, and Atrazine Kidney Injury

  2026-08-13

  This study identifies RIPK3-dependent necroptosis as a central mechanism of atrazine-induced renal tubular injury and shows that melatonin suppresses this pathway. Its combination of animal, cellular, genetic, and computational evidence provides a useful framework for studying chemical nephrotoxicity and testing mechanism-based interventions.

• Tetrahydromagnolol: From GPCR Bias to Cell Motility

  2026-08-12

  Tetrahydromagnolol is a selective peripheral CB2 receptor agonist with a complementary GPR55-antagonist profile. This article develops a mechanistic framework for connecting receptor pharmacology with cytoskeletal and motility assays, while defining which conclusions are established and which require validation.

• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-08-12

  Zhao and colleagues present a standardized whole-blood stimulation protocol that combines defined immune challenges with metabolic pathway modulation and cytokine measurement. Its main contribution is methodological: it provides a reproducible framework for comparing immunometabolic responses across donors and experimental conditions while preserving the cellular and plasma context of whole blood.

• Tetrahydromagnolol: From CB2 Biology to Translation

  2026-08-11

  Tetrahydromagnolol offers translational researchers a selective pharmacology tool for connecting peripheral CB2 receptor signaling with rigorous pathway and phenotype studies. By placing its CB2 agonism and GPR55 antagonism alongside new evidence for GPCR-driven ERM activation in triple-negative breast cancer, this article defines a disciplined framework for mechanistic validation without overstating cross-domain evidence.

• Trametinib: A Pathway-Causal Assay Strategy

  2026-08-11

  Trametinib and GSK1120212 are powerful tools for connecting MEK-ERK target engagement with cell fate and endothelial phenotypes. This article develops a pathway-causal assay framework grounded in cancer biology and a murine lupus lung-injury study.

• Etomoxir for Fatty Acid Oxidation Research

  2026-08-10

  Etomoxir enables controlled fatty acid oxidation pathway research in whole-blood, cellular, and disease-model workflows. Its strongest use-case is metabolic perturbation paired with cytokine, lipid, and viability readouts, while dose-dependent DGAT activity requires careful interpretation.

• RNA Pol II Degradation and Transcription-Independent Death

  2026-08-09

  The preprint argues that RNA polymerase II degradation can activate regulated cell death through a mechanism distinct from transcriptional shutdown. Its central implication is that loss of the hypophosphorylated Pol II IIA pool may function as a death signal, providing a framework for separating transcriptional effects from cytotoxic signaling in mechanistic cancer research.

• GSK-923295 for CENP-E Mitotic Assays

  2026-08-08

  GSK-923295 provides a reversible, concentration-controlled way to induce CENP-E-dependent mitotic disruption and quantify chromosome-alignment defects. Its strongest use is as a mechanistic companion to rapid CTCF depletion, helping researchers distinguish motor-driven congression failure from broader centromere-architecture defects.

15301 records 1/1021 page Next 12345 下5页 Last page